Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1238 clinical trials
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

The purpose of the CliniMACS TCR-Biotin System and CliniMACS CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy.

direct bilirubin
hla-drb1
hla-a
arrhythmia
congestive heart failure
  • 0 views
  • 16 Feb, 2024
  • 1 location
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .

myelodysplastic syndrome
raeb
stem cell transplantation
cag protocol
myelodysplastic syndromes
  • 0 views
  • 16 Feb, 2024
  • 1 location
Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT in Nijmegen breakage syndrome

  • 0 views
  • 05 Aug, 2020
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Thus adding bortezomib, may improve the remission rate, thus bridging to allogeneic stem cell transplant. Adding bortezomid in the relapsed chemotherapy protocol may increase the toxicity and even treatment related mortality.

leukemic cells
pediatric
bortezomib injection
testicular
flow cytometry
  • 0 views
  • 16 Feb, 2024
  • 1 location
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

  • 0 views
  • 16 Feb, 2024
  • 2 locations
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

pediatric
priapism
karnofsky performance status
analgesia
gene therapy
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

Background Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work. Other patients must get blood transfusions regularly which are time consuming and can have significant side effects. The drug eltrombopag can increase red blood cells. Researchers want to see if it …

bone marrow biopsy
blood transfusion
cell counts
blood cell count
corticosteroids
  • 0 views
  • 16 Feb, 2024
  • 1 location
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study …

acute graft-versus-host disease
ruxolitinib
graft versus host disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease

To evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells transplantation in patients with COPD

lung disorder
pulmonary disease
  • 0 views
  • 05 Aug, 2020
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line …

myelodysplastic syndrome
stem cell transplantation
chronic myelomonocytic leukemia
leukemia
cell transplantation
  • 0 views
  • 16 Feb, 2024
  • 23 locations